Azmi Y, Alkaff F, Soetanto K, Wirjopranoto S, Postma M, Purba A
Syst Rev. 2025; 14(1):25.
PMID: 39871381
PMC: 11770980.
DOI: 10.1186/s13643-024-02746-3.
Mederle A, Dumitrescu P, Borza C, Kundnani N
J Clin Med. 2025; 14(1.
PMID: 39797270
PMC: 11721703.
DOI: 10.3390/jcm14010188.
Kowalska J, Wrzesniok D
Pharmaceuticals (Basel). 2024; 17(7).
PMID: 39065698
PMC: 11280276.
DOI: 10.3390/ph17070847.
Suciu I, Grelus A, Cozlac A, Suciu B, Stoica S, Luca S
Medicina (Kaunas). 2024; 60(5).
PMID: 38793020
PMC: 11122753.
DOI: 10.3390/medicina60050837.
Liu H
Front Med (Lausanne). 2024; 11:1301105.
PMID: 38681048
PMC: 11046704.
DOI: 10.3389/fmed.2024.1301105.
Fournier's Gangrene: A Coexistence or Consanguinity of SGLT-2 Inhibitor Therapy.
Chowdhury T, Gousy N, Bellamkonda A, Dutta J, Zaman C, Zakia U
Cureus. 2022; 14(8):e27773.
PMID: 36106208
PMC: 9450557.
DOI: 10.7759/cureus.27773.
Management of Fournier's gangrene during the Covid-19 pandemic era: make a virtue out of necessity.
Paladini A, Cochetti G, Tancredi A, Mearini M, Vitale A, Pastore F
Basic Clin Androl. 2022; 32(1):12.
PMID: 35850577
PMC: 9294754.
DOI: 10.1186/s12610-022-00162-y.
Sodium-Glucose Cotransporter 2 Inhibitor Use Associated With Fournier's Gangrene: A Review of Case Reports and Spontaneous Post-Marketing Cases.
Tran B, Updike W, Bullers K, Serag-Bolos E
Clin Diabetes. 2022; 40(1):78-86.
PMID: 35221476
PMC: 8865791.
DOI: 10.2337/cd21-0015.
Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations.
Klen J, Dolzan V
Int J Mol Sci. 2021; 22(18).
PMID: 34575958
PMC: 8466905.
DOI: 10.3390/ijms22189800.
Fournier Gangrene in a Patient With Type 2 Diabetes Mellitus Treated With Dapagliflozin: A Case Report.
Moon J, Lee M, Kim J, Ha G
Ann Coloproctol. 2021; 37(Suppl 1):S48-S50.
PMID: 34044501
PMC: 8359693.
DOI: 10.3393/ac.2020.06.22.
Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis.
Cai R, Xu Y, Su Q
Cardiol Res Pract. 2021; 2021:6657380.
PMID: 33859839
PMC: 8026320.
DOI: 10.1155/2021/6657380.
Fournier's gangrene with dapagliflozin in a rural hospital: a case report.
Elbeddini A, Tayefehchamani Y, Davey M, Gallinger J, Hooda N, Aly A
BMJ Case Rep. 2021; 14(2).
PMID: 33526523
PMC: 7852914.
DOI: 10.1136/bcr-2020-237784.
Fournier's gangrene under SGLT-2 inhibitor therapy: A literature review and case report.
Ellegard L, Prytz M
Int J Surg Case Rep. 2021; 77:692-694.
PMID: 33395875
PMC: 7711186.
DOI: 10.1016/j.ijscr.2020.11.100.
A Case of Fournier's Gangrene in a Patient Taking Canagliflozin for the Treatment of Type II Diabetes Mellitus.
Elbeddini A, Gallinger J, Davey M, Brassard S, Gazarin M, Plourde F
Am J Case Rep. 2020; 21:e920115.
PMID: 32089542
PMC: 7061930.
DOI: 10.12659/AJCR.920115.
Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier's gangrene.
Yang J, Wang T, Pate V, Buse J, Sturmer T
BMJ Open Diabetes Res Care. 2020; 8(1).
PMID: 31958306
PMC: 7039596.
DOI: 10.1136/bmjdrc-2019-000985.
Fournier's Gangrene and Intravenous Drug Abuse: an Unusual Case Report and Review of The Literature.
Del Zingaro M, Boni A, Rossi de Vermandois J, Paladini A, Lepri E, Ursi P
Open Med (Wars). 2020; 14:694-710.
PMID: 31934634
PMC: 6947763.
DOI: 10.1515/med-2019-0114.
Pharmacovigilance assessment of the association between Fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors.
Fadini G, Sarangdhar M, De Ponti F, Avogaro A, Raschi E
BMJ Open Diabetes Res Care. 2019; 7(1):e000725.
PMID: 31641524
PMC: 6777404.
DOI: 10.1136/bmjdrc-2019-000725.
Fournier's Gangrene in a Patient with Type 2 Diabetes Mellitus Treated with Empagliflozin: A Case Report.
Nagano Y, Yakame N, Aoki H, Yamakawa T, Kondo N
Drug Saf Case Rep. 2019; 6(1):11.
PMID: 31628552
PMC: 6800415.
DOI: 10.1007/s40800-019-0105-8.
Early Presentation of a Rare Complication of Sodium-Glucose Cotransporter-2 Inhibitors 10 Days After Initiation: Case Report and Literature Review.
Elshimy G, Correa R, Alsayed M, Jyothinagaram S
Cureus. 2019; 11(7):e5173.
PMID: 31423402
PMC: 6695297.
DOI: 10.7759/cureus.5173.
